Cargando…

Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry

Aim: This study aimed to describe the prescription patterns of second-line medications for patients with diabetes from selected centers in Costa Rica and Panama. Methods: DISCOVER is a registry of patients with type 2 diabetes switching from first- to second-line medications. We analyzed medication...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen-Ku, Chih H, Grimaldo de Sucre, Pilar, Vinocour, Mary, Ramírez-Zamora, Luis C, Andrés-Jiménez, Fernando, Slon-Hitti, Claudio, Cob, Alejandro, Rodríguez, Guiselle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328805/
https://www.ncbi.nlm.nih.gov/pubmed/34354876
http://dx.doi.org/10.7759/cureus.16060
_version_ 1783732375968022528
author Chen-Ku, Chih H
Grimaldo de Sucre, Pilar
Vinocour, Mary
Ramírez-Zamora, Luis C
Andrés-Jiménez, Fernando
Slon-Hitti, Claudio
Cob, Alejandro
Rodríguez, Guiselle
author_facet Chen-Ku, Chih H
Grimaldo de Sucre, Pilar
Vinocour, Mary
Ramírez-Zamora, Luis C
Andrés-Jiménez, Fernando
Slon-Hitti, Claudio
Cob, Alejandro
Rodríguez, Guiselle
author_sort Chen-Ku, Chih H
collection PubMed
description Aim: This study aimed to describe the prescription patterns of second-line medications for patients with diabetes from selected centers in Costa Rica and Panama. Methods: DISCOVER is a registry of patients with type 2 diabetes switching from first- to second-line medications. We analyzed medication choice and the reasons to switch for each country.  Results: A total of 219 patients were included during 2014-2016, 127 in Costa Rica and 92 in Panama. The most frequently prescribed first-line medication was metformin, followed by sulphonylureas in Panama, and a combination of metformin and dipeptidyl peptidase-4 inhibitor (iDPP4) in Costa Rica. DPP4 inhibitors plus metformin was the most commonly prescribed second-line medication, followed by metformin combined with sodium-glucose transport protein-2 inhibitor (iSGLT2) in Costa Rica and iDPP4 in monotherapy in Panama. The main reason to switch being efficacy. When choosing the second-line medication, the main reasons behind the switch were efficacy, weight loss, and hypoglycemia risk in both countries (tolerability being also common in Panama). Conclusions: According to the DISCOVER registry, in Costa Rica and Panama, efficacy is the most common reason to switch to second-line medication. Metformin plus iDPP4 was the most commonly prescribed agent.
format Online
Article
Text
id pubmed-8328805
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-83288052021-08-04 Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry Chen-Ku, Chih H Grimaldo de Sucre, Pilar Vinocour, Mary Ramírez-Zamora, Luis C Andrés-Jiménez, Fernando Slon-Hitti, Claudio Cob, Alejandro Rodríguez, Guiselle Cureus Endocrinology/Diabetes/Metabolism Aim: This study aimed to describe the prescription patterns of second-line medications for patients with diabetes from selected centers in Costa Rica and Panama. Methods: DISCOVER is a registry of patients with type 2 diabetes switching from first- to second-line medications. We analyzed medication choice and the reasons to switch for each country.  Results: A total of 219 patients were included during 2014-2016, 127 in Costa Rica and 92 in Panama. The most frequently prescribed first-line medication was metformin, followed by sulphonylureas in Panama, and a combination of metformin and dipeptidyl peptidase-4 inhibitor (iDPP4) in Costa Rica. DPP4 inhibitors plus metformin was the most commonly prescribed second-line medication, followed by metformin combined with sodium-glucose transport protein-2 inhibitor (iSGLT2) in Costa Rica and iDPP4 in monotherapy in Panama. The main reason to switch being efficacy. When choosing the second-line medication, the main reasons behind the switch were efficacy, weight loss, and hypoglycemia risk in both countries (tolerability being also common in Panama). Conclusions: According to the DISCOVER registry, in Costa Rica and Panama, efficacy is the most common reason to switch to second-line medication. Metformin plus iDPP4 was the most commonly prescribed agent. Cureus 2021-06-30 /pmc/articles/PMC8328805/ /pubmed/34354876 http://dx.doi.org/10.7759/cureus.16060 Text en Copyright © 2021, Chen-Ku et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Chen-Ku, Chih H
Grimaldo de Sucre, Pilar
Vinocour, Mary
Ramírez-Zamora, Luis C
Andrés-Jiménez, Fernando
Slon-Hitti, Claudio
Cob, Alejandro
Rodríguez, Guiselle
Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry
title Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry
title_full Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry
title_fullStr Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry
title_full_unstemmed Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry
title_short Diabetes Second-Line Medication Prescription Patterns in Costa Rica and Panama: Evidence From the DISCOVER Registry
title_sort diabetes second-line medication prescription patterns in costa rica and panama: evidence from the discover registry
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328805/
https://www.ncbi.nlm.nih.gov/pubmed/34354876
http://dx.doi.org/10.7759/cureus.16060
work_keys_str_mv AT chenkuchihh diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT grimaldodesucrepilar diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT vinocourmary diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT ramirezzamoraluisc diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT andresjimenezfernando diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT slonhitticlaudio diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT cobalejandro diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry
AT rodriguezguiselle diabetessecondlinemedicationprescriptionpatternsincostaricaandpanamaevidencefromthediscoverregistry